NCT01845727View on ClinicalTrials.gov

Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

July 31, 2016

Conditions
Cutaneous Leishmaniasis
Interventions
DRUG

Topical Amphotericin B at 3%

Trial Locations (1)

Unknown

Programa de Estudios y Control de Enfermedades Tropicales (PECET), Universidad de Antioquia, Medellín

All Listed Sponsors
lead

Drugs for Neglected Diseases

OTHER

NCT01845727 - Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia | Biotech Hunter | Biotech Hunter